Physics-Powered GenAI Biotech Gero Raises $6M to Find Root Causes of Aging and Age-Related Diseases
Retrieved on:
Wednesday, October 18, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Artificial Intelligence, Genetics, Science, Longevity, Ageing, Notifiable disease, NYSE, Therapy, Calico (company), Hope, Human, Conditional sentence, BioRxiv, LLM, Phenotype, Investment, Popular Mechanics, Mouse, Quality of life, Pfizer, LHM, Nature Communications, Altos Labs, Biology, Mechanics, American Association for the Advancement of Science, VC, Herbert Wertheim School of Public Health and Human Longevity Science, Pharmaceutical industry, Medical device, Dietary supplement, Amazon
Gero , a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.
Key Points:
- Gero , a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.
- By applying cutting-edge generative AI tools to analyze real-world longitudinal human health data, Gero is dedicated to finding novel cures for age-related diseases.
- Its goal is to unravel the mysteries behind human aging and halt the aging process.
- Gero’s approach allows separating the effects of aging from the effects of diseases enabling human genetics-driven target discovery for chronic and age-related diseases.